NEOS Investment Management LLC Has $5.02 Million Holdings in BridgeBio Pharma, Inc. $BBIO

NEOS Investment Management LLC trimmed its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 21.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,561 shares of the company’s stock after selling 27,026 shares during the quarter. NEOS Investment Management LLC’s holdings in BridgeBio Pharma were worth $5,015,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of BBIO. Skandinaviska Enskilda Banken AB publ grew its position in shares of BridgeBio Pharma by 152.1% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 148,917 shares of the company’s stock worth $7,735,000 after purchasing an additional 89,856 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of BridgeBio Pharma by 2.1% in the third quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after buying an additional 347,074 shares during the period. Assetmark Inc. grew its position in BridgeBio Pharma by 57.2% during the third quarter. Assetmark Inc. now owns 4,418 shares of the company’s stock worth $229,000 after buying an additional 1,608 shares in the last quarter. Cibc World Market Inc. acquired a new stake in BridgeBio Pharma during the third quarter worth approximately $1,024,000. Finally, Stratos Wealth Partners LTD. bought a new position in BridgeBio Pharma during the 3rd quarter worth $350,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

Insider Activity at BridgeBio Pharma

In related news, CFO Thomas Trimarchi sold 13,600 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares in the company, valued at $25,149,631.20. The trade was a 3.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total value of $754,600.00. Following the completion of the transaction, the director directly owned 11,589 shares of the company’s stock, valued at approximately $874,505.94. The trade was a 46.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 176,121 shares of company stock worth $13,009,631. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma Trading Down 2.5%

BBIO opened at $73.93 on Thursday. The company has a market cap of $14.25 billion, a P/E ratio of -17.69 and a beta of 1.13. The company’s 50 day moving average is $75.73 and its 200-day moving average is $63.79. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BBIO. Barclays assumed coverage on BridgeBio Pharma in a research report on Wednesday, January 28th. They set an “overweight” rating for the company. Evercore reaffirmed an “outperform” rating on shares of BridgeBio Pharma in a research report on Monday, October 27th. JPMorgan Chase & Co. raised their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Sanford C. Bernstein began coverage on shares of BridgeBio Pharma in a report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price target for the company. Finally, The Goldman Sachs Group increased their price target on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $82.05.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.